



Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	October 15, 2020

DOJOLVI™ (triheptanoin)

**LENGTH OF AUTHORIZATION:** UP TO ONE YEAR

**REVIEW CRITERIA:**

- Patient has confirmed diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD)
- Confirm discontinuation of other medium-chain triglyceride (MCT) products prior to use
- Must be prescribed by a clinical specialist knowledgeable in appropriate disease-related dietary management

**DOSING AND ADMINISTRATION:**

- The recommended target daily dosage of DOJOLVI is up to 35% of the patient's total prescribed daily caloric intake (DCI) divided into at least four doses

$$Total\ Daily\ Dose\ ( \_\_ mL) = \frac{Patients\ DCI\ ( \_\_ kcal) \times Target\ \_\_ \% \text{ dose of DCI}}{8.3 \frac{kcal}{mL} \text{ of DOJOLVI}}$$

**DOSAGE FORM:**

- 500mL oral solution containing 100% w/w of triheptanoin